Pathstone Family Office’s Recursion Pharmaceuticals RXRX Stock Holding History

Pathstone Family Office’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$93.3K	Buy	+12,196	New	+$122K	﹤0.01%	1592

Other funds holding RXRX

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

DCI

Data Collective IV Palo Alto, California $78.6M AUM 55.41% 1-Year Est. Return

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Pathstone Family Office's RXRX Position: Q3 2023 in Review

Pathstone Family Office opened a new position in Recursion Pharmaceuticals (RXRX) in Q3 2023: 12,196 shares worth $93.3K. The stake represents ﹤0.01% of the portfolio and ranks #1592 among its holdings.

191 funds tracked by Wall St. Rank hold RXRX as of Q3 2023.

Pathstone Family Office held 12,196 shares of Recursion Pharmaceuticals worth $93.3K as of Q3 2023.
Recursion Pharmaceuticals was a new Pathstone Family Office position in Q3 2023.
Recursion Pharmaceuticals made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1592 holding.
191 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.